Alembic Pharma gets US health regulator FDAs nod for scalp psoriasis treatment drug
Alembic Pharmaceuticals said it has received final approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Betamethasone Valerate Foam.
Alembic Pharmaceuticals on Monday said it has received approval from the US health regulator to market a generic medication used to treat moderate-to-severe psoriasis of the scalp.
The company has received final approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Betamethasone Valerate Foam, the drug firm said in a statement.
The approved ANDA is therapeutically equivalent to the reference listed drug product Luxiq Foam (0.12 per cent), of Norvium Bioscience, LLC (Norvium).
Betamethasone valerate foam is a topical corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp.
Shares of Alembic Pharmaceuticals on Monday ended 0.97 per cent down at Rs 1,089.90 apiece on the BSE.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.